Ponazuril 150 Mg/G Oral Paste

Verify with FDA CVM →

62 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
62
Total Reports
6
Deaths Reported
970.0%
Death Rate

Active Ingredients

Ponazuril 150 Mg/G Oral Paste

Administration Routes

OralUnknown

Species Affected

Horse 27
Unknown 18
Dog 10
Cat 4
Goat 1
Human 1
Other Rodents 1

Most Affected Breeds

Unknown 20
Quarter Horse 11
Thoroughbred 4
Horse (unknown) 3
Domestic Shorthair 3
Irish Cob (Tinker) 2
Hanovarian 2
Tennessee Walking Horse 1
Warmblood (unspecified) 1
Goat (unknown) 1

Most Reported Reactions

Product Defect, General 13
Lethargy (see also Central nervous system depression in 'Neurological') 7
Lack of efficacy - NOS 7
Recumbency 5
Lack of efficacy (protozoa) - NOS 5
Fever 5
Death 5
Ataxia 4
Hives (see also 'Skin') 3
Increased sweating 3
Not eating 3
Blistering (see also Application site SOC) 2

Outcome Breakdown

Outcome Unknown
27 (61.4%)
Ongoing
6 (13.6%)
Died
5 (11.4%)
Recovered/Normal
5 (11.4%)
Euthanized
1 (2.3%)

Data Summary

Metric Value
Total adverse event reports 62
Reports involving death 6
Case-fatality rate (reported events) 970.0%
Distinct species in reports 7
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Ponazuril 150 Mg/G Oral Paste Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 62 adverse event reports referencing Ponazuril 150 Mg/G Oral Paste, including 6 reports in which the animal died — a 970.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Ponazuril 150 Mg/G Oral Paste. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Ponazuril 150 Mg/G Oral Paste reports are Horse (27 reports), Unknown (18 reports), Dog (10 reports), with Horse accounting for the largest share. Within those species, Unknown (20), Quarter Horse (11), Thoroughbred (4) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Ponazuril 150 Mg/G Oral Paste are Product Defect, General (13), Lethargy (see also Central nervous system depression in 'Neurological') (7), Lack of efficacy - NOS (7), Recumbency (5). Of the 44 reports with a coded outcome, Outcome Unknown is the leading category at 61.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Ponazuril 150 Mg/G Oral Paste.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial